Use of LDH and autoimmune side effects to predict response to ipilimumab treatment
Background: Ipilimumab is a cytotoxic T-lymphocyte antigen-4 antibody that enhances T-cell activity and proliferation. Methods: In a retrospective analysis of 86 patients the clinical benefits of ipilimumab treatment were correlated with laboratory and clinical data. Results: A lactate dehydrogenase...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
3 August 2016
|
| In: |
Immunotherapy
Year: 2016, Jahrgang: 8, Heft: 9, Pages: 1033-1044 |
| ISSN: | 1750-7448 |
| DOI: | 10.2217/imt-2016-0083 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.2217/imt-2016-0083 Verlag, Volltext: https://www.futuremedicine.com/doi/abs/10.2217/imt-2016-0083 
|
| Verfasserangaben: | J Dick, N Lang, A Slynko, A Kopp-Schneider, C Schulz, A Dimitrakopoulou-Strauss, AH Enk, and JC Hassel |
| Zusammenfassung: | Background: Ipilimumab is a cytotoxic T-lymphocyte antigen-4 antibody that enhances T-cell activity and proliferation. Methods: In a retrospective analysis of 86 patients the clinical benefits of ipilimumab treatment were correlated with laboratory and clinical data. Results: A lactate dehydrogenase (LDH) value within the normal range before the start of therapy was significantly correlated with better OS (p ≤ 0.009). An increase in LDH level after two cycles was indicative of a poor outcome, and was significantly negatively correlated with treatment response and overall survival and progression-free survival. 42% of all patients suffered from autoimmune toxicity (CTCAE grades 2-4). The occurrence of autoimmune toxicity clearly correlated with clinical benefit. Conclusion: Changes in LDH level and side effects correlate with response to therapy and survival. |
|---|---|
| Beschreibung: | Gesehen am 28.02.2018 |
| Beschreibung: | Online Resource |
| ISSN: | 1750-7448 |
| DOI: | 10.2217/imt-2016-0083 |